ArriVent BioPharma, Inc. (AVBP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$62.1M
Cash & Equivalents
$41.9M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$1,569M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small... | PHASE3 | Active Not Recruiting | 398 |
| NCT07185997 | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li... | PHASE3 | Recruiting | 480 |
| NCT07066657 | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | PHASE1 | Recruiting | 405 |
| NCT05364073 | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Inclu... | PHASE1 | Active Not Recruiting | 160 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.